SEARCH

SEARCH BY CITATION

References

  • 1
    Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005; 366(9499):180920.
  • 2
    Giannobile WV. Host-response therapeutics for periodontal diseases. J Periodontol. 2008; 79(8 Suppl):1592600.
  • 3
    Kinney JS, Ramseier CA, Giannobile WV. Oral fluid-based biomarkers of alveolar bone loss in periodontitis. Ann NY Acad Sci. 2007; 1098:23051.
  • 4
    Murphy KG, Gunsolley JC. Guided tissue regeneration for the treatment of periodontal intrabony and furcation defects. A systematic review. Ann Periodontol. 2003; 8(1):266302.
  • 5
    Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012; 33(5):74783.
  • 6
    Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280(29):267705.
  • 7
    Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):198837.
  • 8
    Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone. 2005; 36(6):9437.
  • 9
    Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10(5):53743.
  • 10
    Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68(3):57789.
  • 11
    Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23(6):8609.
  • 12
    Opar A. Late-stage osteoporosis drugs illustrate challenges in the field. Nat Rev Drug Discov. 2009; 8(10):7578.
  • 13
    Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24(4):57888.
  • 14
    Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011; 26(5):101221.
  • 15
    Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26(1):1926.
  • 16
    Jin Q, Cirelli JA, Park CH, Sugai JV, Taba M Jr, Kostenuik PJ, Giannobile WV. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol. 2007; 78(7):13008.
  • 17
    Cirelli JA, Park CH, MacKool K, Taba M Jr, Lustig KH, Burstein H, Giannobile WV. AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression. Gene Ther. 2009; 16(3):42636.
  • 18
    Park CH, Abramson ZR, Taba M Jr, Jin Q, Chang J, Kreider JM, Goldstein SA, Giannobile WV. Three-dimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair. J Periodontol. 2007; 78(2):27381.
  • 19
    Albers J, Schulze J, Beil FT, Gebauer M, Baranowsky A, Keller J, Marshall RP, Wintges K, Friedrich FW, Priemel M, Schilling AF, Rueger JM, Cornils K, Fehse B, Streichert T, Sauter G, Jakob F, Insogna KL, Pober B, Knobeloch KP, Francke U, Amling M, Schinke T. Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol. 2011; 192(6):105772.
  • 20
    Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013; 28(1):7380.
  • 21
    Jawad MU, Fritton KE, Ma T, Ren PG, Goodman SB, Ke HZ, Babij P, Genovese MC. Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. J Orthop Res. 2013; 31(1):15563.
  • 22
    McDonald MM, Morse A, Mikulec K, Peacock L, Yu N, Baldock PA, Birke O, Liu M, Ke HZ, Little DG. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res. 2012; 30(10):15418.
  • 23
    Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res. 2010; 25(9):1897904.
  • 24
    Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, Robinson MK. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009; 24(10):166271.
  • 25
    Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010; 25(12):264756.
  • 26
    Shahnazari M, Wronski T, Chu V, Williams A, Leeper A, Stolina M, Ke HZ, Halloran B. Early response of bone marrow osteoprogenitors to skeletal unloading and sclerostin antibody. Calcif Tissue Int. 2012; 91(1):508.
  • 27
    Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, Westendorf JJ, Singh RJ, Kumar R. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA. 2013; 110(15):6199204.
  • 28
    Bonnet N, Conway SJ, Ferrari SL. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci USA. 2012; 109(37):1504853.
  • 29
    Galli C, Passeri G, Macaluso GM. Osteocytes and WNT: the mechanical control of bone formation. J Dent Res. 2010; 89(4):33143.
  • 30
    Spatz J, Ellman R, Cloutier A, Louis L, van Vliet M, Suva L, Dwyer D, Stolina M, Ke H, Bouxsein M. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res. 2013; 28:86574.
  • 31
    McCauley LK, Somerman MJ. editors. Mineralized tissues in oral and craniofacial science: biological principles and clinical correlates. 1st ed. Hoboken, (NJ): John Wiley & Sons, Inc; Table 9.1, A comparison of characteristic clinical features of VBD and sclerosteosis; 2012,75 p.
  • 32
    Stephen LX, Hamersma H, Gardner J, Beighton P. Dental and oral manifestations of sclerosteosis. Int Dent J. 2001; 51(4):28790.
  • 33
    van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, Oostenbroek HJ, Van Hul W, Hamersma H, Dikkers FG, Hamdy NA, Papapoulos SE, Lowik CW. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009; 88(6):56974.
  • 34
    Lehnen SD, Gotz W, Baxmann M, Jager A. Immunohistochemical evidence for sclerostin during cementogenesis in mice. Ann Anat. 2012; 194(5):41521.